EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Subtherapeutic triazole concentrations as result of a drug-drug interaction with lumacaftor/ivacaftor

T J L Smeets, H van der Sijs, H M Janssens, E J Ruijgrok, B C M de Winter

Journal of Cystic Fibrosis · 2024

DOI: 10.1016/j.jcf.2024.01.006 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Cystic Fibrosis, 2024. Verfasst von T J L Smeets und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pharmacy, Erasmus MC University Medical Center Rotterdam, PO Box 2040, Rotterdam 3015 GD, the Netherlands. Hauptthemen laut MEDLINE: Drug Interactions, Cystic Fibrosis, Quinolones, Drug Combinations. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lumacaftor/ivacaftor (Orkambi®, LUM/IVA) is indicated for the treatment of cystic fibrosis (CF) patients aged ≥ 2 years with homozygous F580del mutation in the CFTR gene. Triazole fungal agents are used to treat fungal disease in CF. The use of triazoles is limited by pharmacokinetic challenges, such as drug-drug interactions. The most notable drug-drug interaction between triazoles and LUM/IVA is due to strong induction of CYP3A4 and UGT by LUM. In this real-world retrospective observational study, we described the effect of LUM/IVA on the trough concentration of triazoles. Concomitant use of LUM/IVA with itraconazole, posaconazole or voriconazole resulted in subtherapeutic triazole levels in 76% of the plasma samples. In comparison, in patients with triazole agents without LUM/IVA only 30.6% of the plasma samples resulted in subtherapeutic concentrations. Subtherapeutic plasma concentrations of triazoles should be considered in CF patients on LUM/IVA and further research is warranted for other dosing strategies and alternative antifungal therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug InteractionsCystic FibrosisQuinolonesDrug CombinationsTriazolesBenzodioxolesAminophenolsAminopyridinesAntifungal AgentsHumansRetrospective StudiesMaleFemaleChildAdolescentAdultChloride Channel AgonistsVoriconazoleItraconazole

Stichwörter der Autor:innen

Cystic fibrosisDrug-drug interactionLumacaftor/ivacaftorTriazoles

Substanzen

QuinolonesDrug CombinationsTriazolesBenzodioxolesAminophenolslumacaftor, ivacaftor drug combinationAminopyridinesAntifungal AgentsChloride Channel Agonistsposaconazole

Autor:innen und Institutionen

  • Department of Hospital Pharmacy, Erasmus MC University Medical Center Rotterdam, PO Box 2040, Rotterdam 3015 GD, the Netherlands.
  • Department of Pediatric Pulmonology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands.
  • Department of Hospital Pharmacy, Erasmus MC University Medical Center Rotterdam, PO Box 2040, Rotterdam 3015 GD, the Netherlands. Electronic address: b.dewinter@erasmusmc.nl.

Zitieren

APA

Smeets, T. J. L., van der Sijs, H., Janssens, H. M., Ruijgrok, E. J., & de Winter, B. C. M. (2024). Subtherapeutic triazole concentrations as result of a drug-drug interaction with lumacaftor/ivacaftor. Journal of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2024.01.006

Vancouver

Smeets TJL, van der Sijs H, Janssens HM, Ruijgrok EJ, de Winter BCM. Subtherapeutic triazole concentrations as result of a drug-drug interaction with lumacaftor/ivacaftor. Journal of Cystic Fibrosis. 2024. doi:10.1016/j.jcf.2024.01.006

BibTeX
@article{Smeets2024,
  author = {Smeets, T J L and van der Sijs, H and Janssens, H M and Ruijgrok, E J and de Winter, B C M},
  title = {Subtherapeutic triazole concentrations as result of a drug-drug interaction with lumacaftor/ivacaftor},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  doi = {10.1016/j.jcf.2024.01.006}
}
Kostenlos starten →